Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
Stock Information for Axsome Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.